Top-Rated StocksTop-RatedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $46.44 +0.88 (+1.93%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$45.80▼$46.8250-Day Range$36.92▼$47.9452-Week Range$15.44▼$48.61Volume1.10 million shsAverage Volume1.44 million shsMarket Capitalization$7.66 billionP/E RatioN/ADividend YieldN/APrice Target$50.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Revolution Medicines alerts: Email Address Revolution Medicines MarketRank™ Stock AnalysisAnalyst RatingBuy3.08 Rating ScoreUpside/Downside9.1% Upside$50.67 Price TargetShort InterestBearish9.55% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.57Based on 4 Articles This WeekInsider TradingSelling Shares$2.58 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.21) to ($3.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.04 out of 5 starsMedical Sector398th out of 936 stocksBiological Products, Except Diagnostic Industry58th out of 154 stocks 2.5 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevolution Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.55% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Revolution Medicines has recently decreased by 2.05%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 2.0 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Revolution Medicines this week, compared to 4 articles on an average week.Search Interest6 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,578,577.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.21) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Revolution Medicines Stock (NASDAQ:RVMD)Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesJuly 18, 2024 | insidertrades.comRevolution Medicines, Inc. (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 16,667 SharesJuly 17, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 25,000 Shares of StockJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 11, 2024 | insidertrades.comRevolution Medicines, Inc. (NASDAQ:RVMD) Director Sells $94,820.00 in StockJune 28, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 2,000 Shares of StockJuly 24 at 1:57 PM | markets.businessinsider.comOutperform Rating with Raised Price Target for Revolution Medicines Amid Promising Oncology TrialsJuly 19, 2024 | americanbankingnews.comStephen Michael Kelsey Sells 16,667 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockJuly 19, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Price Target Increased to $54.00 by Analysts at BarclaysJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 19, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Revolution Medicines, Inc. Lowered by Wedbush (NASDAQ:RVMD)July 18, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Up After Analyst UpgradeJuly 17, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given New $56.00 Price Target at HC WainwrightJuly 17, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $55.00 at OppenheimerJuly 16, 2024 | americanbankingnews.comBank of America Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $55.00July 16, 2024 | americanbankingnews.comNeedham & Company LLC Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $62.00July 8, 2024 | globenewswire.comRevolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024July 8, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)June 8, 2024 | investorplace.comThe 7 Most Undervalued Under-$50 Stocks to Buy in June 2024See More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$50.67 High Stock Price Target$63.00 Low Stock Price Target$39.00 Potential Upside/Downside+8.8%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-436,370,000.00 Net MarginsN/A Pretax Margin-10,683.22% Return on Equity-36.41% Return on Assets-32.13% Debt Debt-to-Equity RatioN/A Current Ratio18.45 Quick Ratio18.45 Sales & Book Value Annual Sales$11.58 million Price / Sales663.66 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book4.20Miscellaneous Outstanding Shares164,990,000Free Float151,787,000Market Cap$7.69 billion OptionableOptionable Beta1.44 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 62)CEO, President & Chairman Comp: $1.12MMr. Jack Anders (Age 47)Chief Financial Officer Comp: $665.28kMs. Margaret A. Horn J.D. (Age 61)Chief Operating Officer Comp: $811.08kDr. Stephen M. Kelsey FRC Path. (Age 63)FRCP, M.D., President of Research & Development Comp: $812.17kMs. Xiaolin Wang (Age 53)Executive Vice President of Development Comp: $633.74kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 43)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEDr. Reddy's LaboratoriesNYSE:RDYCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 115,844 shares on 7/26/2024Ownership: 0.391%Legato Capital Management LLCBought 20,199 shares on 7/26/2024Ownership: 0.012%China Universal Asset Management Co. Ltd.Sold 12,254 shares on 7/20/2024Ownership: 0.012%Nisa Investment Advisors LLCBought 320 shares on 7/20/2024Ownership: 0.002%Raymond James & AssociatesBought 49,275 shares on 7/19/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $28.68 at the beginning of the year. Since then, RVMD stock has increased by 61.9% and is now trading at $46.44. View the best growth stocks for 2024 here. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.05. The firm's revenue for the quarter was down 100.0% compared to the same quarter last year. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $150 million in an initial public offering (IPO) on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' top institutional shareholders include Bank of New York Mellon Corp (0.39%), Raymond James & Associates (0.05%), Legato Capital Management LLC (0.01%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Rock Ventures Iii LP Third, Thilo Schroeder, Mark A Goldsmith, Stephen Michael Kelsey, Margaret A Horn, Jack Anders, Lorence H Kim, Jeff Cislini, Xiaolin Wang, Sushil Patel and Barbara Weber. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE) and Black Diamond Therapeutics (BDTX). This page (NASDAQ:RVMD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
